Shanghai Maxinovel Pharmaceuticals Co. Ltd. has prepared new drug conjugates consisting of small-molecule drugs bonded to radiolabeled chelating agents through linkers acting as programmed cell death 1 (PDCD1; PD-1; CD279)/PD-1 ligand 1 (PD-L1; CD274) interaction inhibitors.

Pfizer Inc. has reported new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of neurodegeneration.

Ignis Therapeutics (Suzhou) Co. Ltd. has patented new muscarinic M4 receptor positive allosteric modulators (PAMs) potentially useful for the treatment of schizophrenia, bipolar disorder, Huntington’s, Alzheimer’s, inflammatory bowel disease, drug-induced dyskinesia, pain and skin lesions.